Newcastle University

Roles and Responsibilities

Lead a research group investigating metabolic dysfunction in severe mental illness
Honorary Consultant Psychiatrist in Liaison Psychiatry (Northumberland, Tyne and wear NHS Trust)
Senior selector for the MB BS degree programme, Newcastle University
CT1 Selector (Northern Deanery)
Chair, Physical Health Committee, NTW NHS Trust

Qualifications

M.B., B.S. (University of Newcastle)1998
Ph.D. (University of Newcastle)1998
M.R.C.Psych. 2002
C.C.T. (General Psychiatry) 2006

Previous Positions

House Officer in General Medicine to Professors Taylor and Marshall, RVI, Newcastle (1999)
House Officer in General and Gastrointestinal Surgery Mr Bradburn, Wansbeck General Hospital, Northumberland (1999)
SHO Basic Specialist Training in Psychiatry 2000-2002 (Newcastle and Nottingham)
SpR Higher Specialist Training in Psychiatry 2002-2006 (Newcastle)

Memberships

Member of the Royal College of Psychiatrists
British Association for Psychopharmacology
International Society for Bipolar Disorders
International Society for Psychoneuroendocrinology
Society of Biological Psychiatry

Honours and Awards

Medical Research Council (MRC) Intercalated Award (1994)
Foulkes Foundation Fellowship (1994-6)
Foulkes Foundation Travelling Fellowship (1998)
National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award (2005-6)
Department of Health Clinician Scientist Award (2006-2011)

Research Interests

Cardio-metabolic disease in severe mental illness.
Cardiac side effects of psychotropic drugs.
Sleep disorders in mental illness.

Other Expertise

Completed PhD in role of ACE inhibitors in experimental diabetic nephropathy.
Expertise in electron microscopy and stereology.

Current Work

Investigating the relationship between severe mental illness and metabolic disease.
Community study of cardio-metabolic disease in psychiatric patients.
Effects of antipsychotics on the heart.
Sleep disorders in mental illness.

Research Roles

Lead a research group (Principal Investigator) in the Institute of Neuroscience

Postgraduate Supervision

MD and MRes Supervisor

Esteem Indicators

NARSAD Young Investigator award
National Institute of Health Research (NIHR) Clinician Scientist Fellowship

Funding

Department of Health Clinician Scientist Award, 2006-2011 (£792,695)
Newcastle, North Tyneside and Northumberland Mental Health NHS Trust Research Capacity Building Grant, 2005 (~£50,000)
National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award, 2005-6 ($16500 USD)
Mental Health Foundation, 2004 (£1357)

Industrial Relevance

None

Patents

None

Keywords

Schizophrenia, bipolar disorder, diabetes, obesity, metabolism, MRS, metabolic syndrome, Department of Health Clinician Scientist

Undergraduate Teaching

Psychiatry teaching to Stage III/IV MB BS students
Biomedical Sciences

Postgraduate Teaching

Pre-Membership teaching
Diploma in Therapeutics
MRes Supervisor

• Mackin P, Thomas SHL. Atypical antipsychotic drugs. British Medical Journal 2011, 342, d1126.
• Mackin P, Nulkar A, Waton T, Watkinson HMO. Prolactin and smoking status in antipsychotic-treated patients. Journal of Psychopharmacology 2010, epub ahead of print.
• Smith MS, Malik N, Gallagher P, Watson S, Mackin P, Ferrier IN, Young AH. Neurocognitive and neuroendocrine effects of mifepristone (RU-486) in schizophrenia. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2004, Harrogate, UK: Sage Publications Ltd..
• Mackin P, Young AH. Reply to Dr. J-C Shim and colleagues regarding "fluoxetine augmentation of haloperidol in chronic schizophrenia" [J Clin Psychopharmacol 2003;23:520-521] [1]. Journal of Clinical Psychopharmacology 2004. , 24(6), 670-.
• Mackin P. Reply to Fischer & Broderick. Sodium Valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder?. Psychiatric Bulletin 2004, 28(7), 264.
• Mackin P, Young AH. Reply to Shim, et al. regarding Fluoxetine augmentation of haloperidol in chronic schizophrenia. Journal of Clinical Psychopharmacology 2004. , 24(6), 670.
• Ahuja N, Palanichamy N, Mackin P, Lloyd A. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. Journal of Psychopharmacology 2010, 24(1), 125-130.
• Watson S, Mackin P. HPA axis function in mood disorders. Medicine 2009,8 3 97-101.
• Craddock N, Antebi D, Attenburrow M-J, Bailey A, Carson A, Cowen P, Craddock B, Eagles J, Ebmeier K, Farmer A, Fazel S, Ferrier N, Geddes J, Goodwin G, Harrison P, Hawton K, Hunter S, Jacoby R, Jones I, Keedwell P, Kerr M, Mackin P, McGuffin P, MacIntyre DJ, McConville P, Mountain D, O'Donovan MC, Owen MJ, Oyebode F, Phillips M, Price J, Shah P, Smith DJ, Walters J, Woodruff P, Young A, Zammit S. Wake-up call for British psychiatry. British Journal of Psychiatry 2008, 193(1), 6-9.
• Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database of Systematic Reviews 2008. , (1), CD005168.
• Mackin P. Cardiac side effects of psychiatric drugs. Human Psychopharmacology: Clinical and Experimental 2008. , 23(S1), 3-14.
• Hampson LJ, Mackin P, Agius L. Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs. Diabetologia 2007, 50(8), 1743-1751.
• Mackin P, Bishop DR, Watkinson HMO. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007, 7(28).
• Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry 2007, 191, 23-29.
• Barnett AH, Mackin P, Chaudhury I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology 2007, 21(4), 357-373.
• Mackin P, Gallagher P, Watson S, Young A, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Australian and New Zealand Journal of Psychiatry 2007, 41(4), 321-326.
• Mackin P, Targum SD, Kalali A, Rom D, Young AH. Culture and assessment of manic symptoms. British Journal of Psychiatry 2006, 189, 379-380.
• Watson S, Mackin P. HPA axis function in mood disorders. Psychiatry 2006, 5(5), 166-170.
• Thompson JM, Hamilton CJ, Gray JM, Quinn JG, Mackin P, Young AH, Ferrier IN. Executive and visuospatial sketchpad resources in euthymic bipolar disorder: Implications for visuospatial working memory architecture. Memory 2006, 14(4), 437-451.
• Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. Journal of Clinical Psychiatry 2005,66 11 1386-1391.
• Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. Diabetologia 2005,48 2 215-221.
• Mackin P, McAllister-Williams H. Fronto-temporal dementia: remembering images from the past. Neuropsychiatric Disease and Treatment 2005,1 3 281-283.
• Mackin P, Watson S, Ferrier IN. Neurobiology of depression : focus on brain-derived neurotrophic factor, cortisol and their interactions. Depression: Mind & Body 2005,2 1 11-18.
• Daban C, Vieta E, Mackin P, Young AH. The HPA axis in bipolar disorder. Psychiatric Clinics of North America 2005,28 2 469-480.
• Mackin P, Young AH. Bipolar Disorders in Core Psychiatry. London, UK:Saunders,2004.
• Mackin P, Young AH. Diagnosis and treatment of bipolar depression. Progress in Neurology and Psychiatry 2004, 8, 15-19.
• Mackin P, Young AH. Rapid cycling bipolar disorder: Historical overview and focus on emerging treatments. Bipolar Disorders 2004. ,6 6 523-529.
• Mackin P, Young AH. The role of cortisol and depression: exploring new opportunities for treatments. Psychiatric Times 2004,21 92-95.
• Arun CS, Stoddart J, Mackin P, MacLeod JM, New JP, Marshall SM. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 2003,26 7 2144-2149.
• Mackin P, Ball SG, Johnson SJ, Lennard TWJ, Proud G. Parathyroid carcinoma: clinical, biochemical and pathological features of three recent cases. In: 18th Joint Meeting of the British Endocrine Societies. 1999, Bournemouth: Journal of Endocrinology.
• Chowdhury, T.A., Dyer, P.H., Kumar, S., Gough, S.L.C., Gibson, S.P., Rowe, B.R., Smith, P.R., Dronsfield, M.J., Marshall, S.M., Mackin, P., Dean, J.D., Morris, P.J.M., Davies, S.J., Dunger, D.B., Boulton, A.J.M., Barnett, A.H., Bain, S.C. Lack of association of angiotensis II type 1 receptor gene polymorphism with diabetic nephropathy in insulin-dependent diabetes mellitus. Diabetic Medicine 1997, 14, 837-840.
• Chowdhury, T.A., Dronsfield, M.J., Kumar, S., Gough, S.L.C., Gibson, S.P., Khatoon, A., MacDonald, F., Rowe, B.R., Dunger, D.B., Dean, J.D., Davies, S.J., Webber, J., Smith, P.R., Mackin, P., Marshall, S.M., Adu, D., Morris, P.J.M., Todd, J.A., Barnett, A.H., Boulton, A.J.M., Bain, S.C. Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 1996, 39, 1108-1114.
• Mackin, P., MacLeod, J.M., New, J.P., Marshall, S.M. Renal function in long duration Type 1 diabetes mellitus. Diabetes Care 1996, 19, 249-251.
• Mackin P, Waton T, Watkinson HM, Gallagher P. A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients. European Psychiatry 2012, 27(1), 50-55.
• Mackin P, Skinner JS, Farrer M, Albers CJ, Neil HAW, Adams PC. Clinical outcome measures eight years following Coronary Artery Bypass Grafting (CABG): A prospective cohort study. Heart 1999, 81(1), P49-.